Biologics Kill Biosimilars? Limited Originator Uptake Perplexes China Biogenerics Market
Although hope is high for the first follow-on biologic to take off in the world's second-largest pharma market, China's biosimilar developers see choppy waters ahead. Biosimilars are not only limited by uncertain pricing and murky interchangeability rules, but also by extremely low biologic penetration and developers rushing to develop I/O and cell therapies.
You may also be interested in...
From requiring early notification to whole-process involvement, China is clearing a path for a far-reaching new biosecurity law, which if implemented will pose high hurdles for international firms planning to conduct clinical studies in the country, industry observers say.
In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.
Developing some of the first coronavirus vaccines and antibody testing kits, venture-backed firms in China have responded fast and partnered actively in the fight against the pandemic, helping them to raise new funds and reach deals. But there have been cautionary tales in other sectors and some investors remain wary.